A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...

This was the stock's second consecutive day of losses.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other top stocks to buy according to Two Sigma Investments. Two Sigma Investments, LP ...

Eli Lilly & Co. is adding Alzheimer’s disease resources to the online platform it launched a year ago to sell obesity, diabetes and migraine medicines. Patients will now be able to use ...

He also recommends avoiding Eli Lilly (LLY), as its tremendous revenue growth is hard to repeat. To watch more expert insights and analysis on the latest market action, check out more Market ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks to buy now for the long term. The US equity markets have started to show ...